Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 4/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.53 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SFRP1 | Q8N474 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15504588 | 0.91 | STS (0.55) | STSGPR119CCR8MEN1KMT2A | |
| SCHEMBL6195397 | 0.87 | STS (0.58) | STSGPR119CCR8SFRP1BRD4 | |
| SCHEMBL2961651 | 0.87 | MMP13 (0.62) | STSGPR119CCR8MEN1KMT2A | |
| SCHEMBL27238580 | 0.86 | STS (0.51) | STSGPR119CCR8MEN1KMT2A | |
| SCHEMBL4602370 | 0.86 | MMP13 (0.63) | STSGPR119CCR8SFRP1BRD4 | |
| SCHEMBL3413300 | 0.86 | STS (0.57) | STSGPR119CCR8SFRP1BRD4 | |
| SCHEMBL7533683 | 0.86 | STS (0.73) | STSGPR119CCR8SFRP1BRD4 | |
| SCHEMBL24169967 | 0.85 | CCR8 (0.57) | STSGPR119CCR8KMT2ASFRP1 | |
| SCHEMBL21292864 | 0.84 | STS (0.57) | STSGPR119CCR8SFRP1MMP13 | |
| SCHEMBL21292730 | 0.84 | STS (0.55) | STSGPR119CCR8SFRP1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759075-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| CN-112041301-A | Compounds having iron death inducing activity and methods of use thereof | 费罗治疗公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | STS 2651/4885GPR119 2189/4885CCR8 3158/4885 |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | AIFM2, GPX4, GPX1 | STS 2115/4885GPR119 2468/4885CCR8 3254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.